ERBA Diagnostics, Inc. is the subject of a securities class action settlement covering investors who purchased ERBA Diagnostics securities on the NYSE between June 14, 2013 and November 20, 2015. The $1,215,000 total settlement provided an average gross recovery of approximately $0.17 per share, or roughly $0.11 per damaged share after fees and expenses. The claim deadline of December 10, 2018 has long since passed — SettleSignal maintains this record for investors researching ERBA's litigation history.